The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective The administration of glucocorticoids usually causes a mild increase in fasting glucose levels and a greater dose-dependent increase in postprandial values in patients without pre-existing diabetes mellitus. Patients with persistent hyperglycemia due to glucocorticoid therapy sometimes require insulin therapy, which might result in increased weight gain and more episodes of hypoglycemia, some of which are severe. On the other hand, scant evidence is available on the efficacy of oral hypoglycemic agents in treating glucocorticoid-induced diabetes. In this study, we evaluated the efficacy of dipeptidyl peptidase (DPP)-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring (CGM). Methods We examined the glycemic profiles using CGM at baseline and 1-4 weeks after initiating DPP-4 inhibitor treatment in patients with newly developed glucocorticoid-induced diabetes. Results Eleven patients who had been diagnosed with kidney disease or other diseases with renal involvement were recruited for the present retrospective study. After starting DPP-4 inhibitors, the mean and standard deviation (SD) of the glucose level, and the mean amplitude of glycemic excursion (MAGE) were significantly improved in comparison to baseline. Furthermore, the area over the curve (AOC) for the glucose levels <70 mg/dL was not increased in comparison to baseline after the initiation of DPP-4 inhibitor treatment. The results indicate that the treatment of patients with glucocorticoid-induced diabetes using DPP-4 inhibitors can minimize the risk of hypoglycemia and reduce glucose variability. Conclusion DPP-4 inhibitors are potentially useful for blood glucose control in patients with glucocorticoid-induced diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266 · cited 1×
“The mechanism by which glucocorticoids cause hyperglycemia is multifactorial and includes the augmentation of hepatic gluconeogenesis, the inappropriate secretion of glucagon, the inhibition of the glucose uptake in adipose tissue, and the alteration of insulin receptor and postreceptor signals (1-4).”
BackgroundUmpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases
Uzu, T., Harada, T., Sakaguchi, M., Kanasaki, M., Isshiki, K., Araki, S., Sugiomoto, T., Koya, D., Haneda, M., Kashiwagi, A., et al. (2006) · Nephron Clinical Practice · doi:10.1159/000097598 · Cited by 136 · cited 1×
“It has been reported that glucocorticoid-induced diabetes is characterized by an increase in postprandial glucose levels (10-12).”
Backgroundvan Raalte, D. H., Diamant, M., Ouwens, D. M., Ijzerman, R. G., Linssen, M. M. L., Guigas, B., Eringa, E. C., & Serné, E. H. (2013) · Diabetologia · doi:10.1007/s00125-013-3016-8 · Cited by 33 · cited 1×
“It has been reported that glucocorticoid-induced diabetes is characterized by an increase in postprandial glucose levels (10-12).”
Background
Cited by
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Management of Glucocorticoid-Induced Hyperglycemia
Shah, P., Kalra, S., Yadav, Y., Deka, N., Lathia, T., Jacob, J. J., Kota, S. K., Bhattacharya, S., Gadve, S. S., Subramanium, K., et al. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s330253 · Cited by 80
“In patients with GC-induced diabetes, DPP-4 inhibitors can minimize the risk of hypoglycemia.(36) DPP-4 inhibitors could be safe and effective antidiabetic drugs for GC-induced diabetes.”
BackgroundGlucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4
Diaz-Jimenez, D., Petrillo, M. G., Busada, J. T., Hermoso, M. A., & Cidlowski, J. A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010894 · Cited by 37
“DPP4 inhibitors, such as linagliptin and sitagliptin (33–36), are useful for the control of blood glucose in type 2 diabetes patients (33) who do not respond well to metformin (34) and sulfonylureas (35) and patients suffering from the diabetogenic effects of glucocorticoids (36, 37).”
BackgroundJain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
“Dipeptidyl peptidase 4 (DPP4) inhibitors have been shown in a small study to reduce the mean amplitude of glycemic excursions in a population who developed glucocorticoid-induced diabetes [20].”
Background
Metadata
- Authors
- Yata, Y., Hosojima, M., Kabasawa, H., Ishikawa, T., Kaseda, R., Iino, N., Suzuki, Y., Saito, A., & Narita, I.
- Venue
- Internal Medicine
- Published
- 2017
- Volume
- 56
- Issue
- 19
- Pages
- 2555-2562
- ISSN
- 0918-2918 (ISSN-L)
- 1349-7235
- OpenAlex
- W2753718881
- Cited by
- 15
- References
- 5
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring. https://app.cochat.ai/papers/10.2169/internalmedicine.8296-16
- The paper
- Yata, Y., Hosojima, M., Kabasawa, H., Ishikawa, T., Kaseda, R., Iino, N., Suzuki, Y., Saito, A., & Narita, I. (2017). The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring. Internal Medicine. https://doi.org/10.2169/internalmedicine.8296-16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.